MDSpire - Summary
Clinical Guidelines
Feature

Japan Clears First iPSC Therapies for Clinical Use 

Two iPSC-derived cell therapies receive time-limited authorization following early clinical trials

  • March 25, 2026

  • 2 min

Share

Japan’s Ministry of Health, Labour and Welfare has made a groundbreaking decision by granting conditional approval to two induced pluripotent stem cell (iPSC)-derived therapies: ReHeart for severe heart failure and Amchepry for Parkinson’s disease. ReHeart aims to repair myocardial function by using cardiomyocyte sheets transplanted onto the heart, while Amchepry seeks to restore lost dopamine-producing neurons. Both therapies received support from earlier clinical trials but require further study to confirm safety and efficacy. This approval is part of Japan's initiative to accelerate the development of regenerative medicine.

Original Source(s)

Japan Clears First iPSC Therapies for Clinical Use 

  • March 25, 2026

Related Content

Gonococcal Endocarditis Diagnosed by PCR

Case highlights diagnostic challenges when blood cultures are negative and embolic complications are present

A Closer Look at Vascular Cell States in Marfan Syndrome

Single-cell proteomics identifies Marfan-enriched smooth muscle states and endothelial transition signatures

  • March 25, 2026

  • 2 min
Suspended Lead Suits Linked to Lower Radiation in LAAO

Study shows suspended lead suits reduce head-level radiation exposure during left atrial appendage occlusion procedures